ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion
RMD•Q4 FY2026 results
- ResMed Q4 FY2026 revenue rose 9% to USD 1.46 billion from June 30, 2025 period; GAAP diluted EPS increased 2% to USD 2.64.
- GAAP operating income slipped 1% to USD 448.71 million; GAAP gross margin narrowed 2 percentage points to 58.8%.
- Non-GAAP diluted EPS climbed 16% to USD 2.95; non-GAAP gross margin widened 0.9 percentage points to 62.3%.
Full-year FY2026 results
- FY2026 revenue increased 10% to USD 5.65 billion; GAAP diluted EPS rose 10% to USD 10.43.
Capital returns and dividend
- Guided to more than USD 1.85 billion of shareholder returns in FY2027; raised quarterly dividend 10% to USD 0.66.
